

Figure S1 Data screening diagram.

Table S1 Characteristics of baselines in the training and validation coh	Table S1 Characteristics of b	baselines in the tr	raining and valid	dation cohorts
--	-------------------------------	---------------------	-------------------	----------------

Variables	Training cohort, N = 62,294 (%)	Validation cohort, $N = 3,327$ (%)
Gender		
Female	33,192 (53.3)	1,452 (43.6)
Male	29,102 (46.7)	1,875 (56.4)
Age, years		
Mean (SD)	68.1 (13.8)	59.9 (11.6)
Tumor size, cm		
Median (SD)	4.5 (2.2)	5.5 (2.1)
Histological grade		
Grade I	5,523 (8.9)	99 (3.0)
Grade II	44,452 (71.4)	2,610 (78.4)
Grade III	11,245 (18.1)	615 (18.5)
Grade IV	1,074 (1.7)	3 (0.1)
AJCC 8 <sup>th</sup> T stage		
T1	5,879 (9.4)	22 (0.7)
T2	10,729 (17.2)	68 (2.0)
Т3	38,359 (61.6)	1,789 (53.8)
T4a	4,352 (7.0)	1,015 (30.5)
T4b	2,975 (4.8)	433 (13.0)
AJCC 8 <sup>th</sup> N stage		
NO	37,998 (61.0)	1,298 (39.0)
N1a	7,694 (12.4)	723 (21.7)
N1b/1c	7,705 (12.4)	709 (21.3)
N2a	4,988 (8.0)	345 (10.4)
N2b	3,909 (6.3)	252 (7.6)
Retrieved lymph nodes		
<12	16,674 (26.8)	1,052 (31.6)
≥12	45,620 (73.2)	2,275 (68.4)
Mean (SD)	17.2 (9.6)	16.7 (10.0)
Adjuvant chemotherapy		
Yes	-	1,582 (47.6)
No	-	1,739 (52.3)
Unknown	-	6 (0.2)

AJCC, American Joint Committee on Cancer; SD, standard deviation.

Variables	Training c	ohort, N=62,294 (%)	Validation cohort, N=3,327 (%)			
Variables	Retrieved LNs < 12	Retrieved LNs ≥ 12	P value	Retrieved LNs < 12	Retrieved LNs ≥ 12	P value
Age, year			<0.001			0.006
≤60 years	4,028 (24.2)	14,330 (31.4)		469 (44.6)	1,131 (49.7)	
>60 years	12,646 (75.8)	31,290 (68.6)		583 (55.4)	1,144 (50.3)	
Gender			<0.001			0.910
Female	8,631 (51.8)	24,561 (53.8)		461 (43.8)	991(43.6)	
Male	8,043 (48.2)	21,059 (46.2)		591 (56.2)	1,284 (56.4)	
Race			0.002			-
White	13,064 (78.3)	36,341 (79.7)		-	-	
Black	2,110 (12.7)	5,457 (12.0)		-	-	
Other	1,500 (9.0)	3,822 (8.4)		-	-	
Tumor size, cm			<0.001			<0.001
≤4.5 cm	11,908 (71.4)	24,647 (54.0)		453 (43.1)	672 (29.5)	
>4.5 cm	4,766 (28.6)	20,973 (46.0)		599 (56.9)	1,603 (70.5)	
Histological grade			<0.001			0.034
Grade I	1,847 (11.1)	3,676 (8.1)		34 (3.2)	65 (2.9)	
Grade II	12,190 (73.1)	32,262 (70.7)		853 (81.1)	1,757 (77.2)	
Grade III	2,455 (14.7)	8,790 (19.3)		164 (15.6)	451 (19.8)	
Grade IV	182 (1.1)	892 (2.0)		1 (0.1)	2 (0.1)	
AJCC 8 <sup>th</sup> pT stage			<0.001			<0.001
pT1	2,420 (14.5)	3,459 (7.6)		13 (1.2)	9 (0.4)	
pT2	3,317 (19.9)	7,412 (16.2)		32 (3.0)	36 (1.6)	
рТ3	9,167 (55.0)	29,192 (64)		481 (45.7)	1,308 (57.5)	
pT4a	1,065 (6.4)	3,287 (7.2)		408 (38.8)	607 (26.7)	
pT4b	705 (4.2)	2,270 (5.0)		118 (11.2)	315 (13.8)	
AJCC 8 <sup>th</sup> pN stage			<0.001			<0.001
pN0	11,022 (66.1)	26,976 (59.1)		451 (42.9)	847 (37.2)	
pN1a	2,103 (12.6)	5,591 (12.3)		243 (23.1)	480 (21.1)	
pN1b	2,038 (12.2)	5,667 (12.4)		234 (22.2)	475 (20.9)	
pN2a	1,166 (7.0)	3,822 (8.4)		93 (8.8)	252 (11.1)	
pN2b	345 (2.1)	3,564 (7.8)		31 (2.9)	221 (9.7)	
Adjuvant chemotherapy			-			0.129
Yes	-	-		521 (49.5)	1,061 (46.6)	
No	-	-		530 (50.4)	1,209 (53.1)	
Unknown	_	_		1 (0.1)	5 (0.3)	

Table S2 Baseline characteristics of the t	training and validation cohorts in relation t	to the number of retrieved lymph nodes

Abbreviations: AJCC, American Joint Committee on Cancer; LNs, lymph nodes.

	Training	cohort, r	LNs <12	Training	cohort, r	LNs ≥12	Validatio	n cohort,	rLNs <12	Validatio	n cohort,	t, rLNs ≥12
Variables	U	UA MA		UA MA		U	IA	MA	UA		MA	
	5-Y OS	Р	P	5-Y OS	Р	Р	5-Y OS	Р	P	5-Y OS	Р	Р
Age, year		<0.001	<0.001		<0.001	<0.001		<0.001	<0.001		<0.001	<0.001
≤60 years	79.4%			82.9%			79.6%			82.0%		
>60 years	57.6%			64.1%			67.6%			73.3%		
Gender		0.886	-		0.092	-		0.509	-		0.045	0.036
Female	62.7%			70.4%			74.7%			79.5%		
Male	62.9%			69.4%			71.6%			76.5%		
Race		<0.001	<0.001		<0.001	<0.001		-	-		-	-
White	62.4%			69.6%			-			-		
Black	60.0%			67.9%			-			-		
Other	70.5%			76.3%			-			-		
Size, cm		< 0.001	<0.001		< 0.001	<0.001		<0.001	0.021		0.013	0.242
≤4.5 cm	66.9%			72.6%			79.2%			81.8%		
>4.5 cm	52.5%			66.8%			68.6%			76.2%		
Histological grade		<0.001	<0.001		<0.001	<0.001		0.005	0.174		<0.001	0.164
Grade I	70.8%			76.8%			100%			70.0%		
Grade II	64.3%			72.0%			73.8%			79.4%		
Grade III	50.3%			60.8%			63.6%			73.2%		
Grade IV	53.8%			56.3%			100%			100%		
AJCC 8 <sup>th</sup> pT stage		< 0.001	<0.001		< 0.001	<0.001		<0.001	<0.001		0.011	<0.001
pT1	80.6%			84.6%			88.9%			100%		
pT2	73.2%			80.3%			92.6%			96.6%		
pT3	58.9%			69.6%			78.8%			77.9%		
pT4a	43.0%			51.5%			70.5%			79.4%		
pT4b	33.2%			44.9%			56.9%			71.9%		
AJCC 8 <sup>th</sup> pN stage		< 0.001	<0.001		< 0.001	<0.001		<0.001	<0.001		<0.001	<0.001
pN0	69.0%			76.9%			76.3%			83.7%		
pN1a	58.1%			70.0%			77.8%			80.5%		
pN1b	52.0%			64.3%			67.3%			77.2%		
pN2a	41.0%			56.2%			66.6%			73.3%		
pN2b	31.1%			40.7%			49.7%			55.5%		
Adjuvant chemother	ару	-	-		-	-		<0.001	<0.001		0.009	<0.001
Yes	-			-			78.8%			80.3%		
No	-			-			67.5%			77.1%		
Unknown	_			-			100%			100%		


Table S3 Univariate and multivariable analyses of prognostic factors in the training and validation cohorts in relation to the number of retrieved lymph nodes

Abbreviations: AJCC, American Joint Committee on Cancer; P, p value; rLNs, retrieved lymph nodes. MA, multivariate analysis; UA, univariate analysis.

Table S4	The prop	posed Ll	NR stage	in the	training cohort	t

Values	5-Y OS, % (95% CI)	HRs (95% CI) <sup>†</sup>	Log-rank (Mantel-Cox) <sup>‡</sup>		
values			$\chi^2$ value	P value	
LNR1	74.5 (74.1-75.0)				
0.00 (n=37,998)	74.6 (74.2-75.0)	1.00 (reference)			
(0.00, 0.05] (n=2,578)	73.7 (71.9-75.3)	0.95 (0.89-1.02)	1.83	0.176	
LNR2	62.4 (61.6-63.1)				
(0.05, 0.10] (n=5,507)	67.3 (66.0-68.5)	1.26 (1.20-1.31)	50.5	<0.001	
(0.10, 0.15] (n=3,229)	62.7 (61.0-64.3)	1.40 (1.33-1.48)	11.2	0.001	
(0.15, 0.20] (n=2,877)	59.6 (57.7-61.3)	1.58 (1.50-1.67)	11.1	0.001	
(0.20, 0.25] (n=1,846)	57.5 (55.2-59.7)	1.66 (1.55-1.77)	1.39	0.238	
(0.25, 0.30] (n=1,266)	53.8 (51.0-56.5)	1.79 (1.66-1.94)	2.25	0.134	
LNR3	48.6 (47.0-50.1)				
(0.30, 0.35] (n=1,182)	49.8 (46.9-52.7)	2.02 (1.87-2.18)	4.52	0.033	
(0.35, 0.40] (n=1,133)	50.0 (47.1-52.9)	2.09 (1.93-2.26)	0.509	0.476	
(0.40, 0.45] (n=672)	47.0 (43.1-50.7)	2.21 (2.00-2.43)	0.821	0.365	
(0.45, 0.50] (n=952)	46.4 (43.2-49.5)	2.22 (2.04-2.40)	0.004	0.95	
LNR4	40.6 (38.1-43.0)				
(0.50, 0.55] (n=277)	39.0 (33.2-44.7)	2.67 (2.31-3.09)	4.50	0.034	
(0.55, 0.60] (n=570)	41.8 (37.7-45.8)	2.52 (2.28-2.79)	0.226	0.634	
(0.60, 0.65] (n=278)	39.4 (33.7-45.1)	2.69 (2.33-3.10)	0.365	0.546	
(0.65, 0.70] (n=391)	40.7 (35.8-45.6)	2.60 (2.31-2.94)	0.04	0.841	
LNR5	26.9 (24.7-29.2)				
(0.70, 0.75] (n=329)	32.1 (27.0-37.2)	3.45 (3.05-3.91)	8.62	0.003	
(0.75, 0.80] (n=255)	27.5 (22.1-33.1)	3.71 (3.22-4.26)	0.682	0.409	
(0.80, 0.85] (n=174)	26.6 (20.3-33.4)	4.09 (3.45-4.85)	0.84	0.359	
(0.85, 0.90] (n=207)	26.3 (20.5-32.5)	4.13 (3.54-4.81)	0	0.987	
(0.90, 0.95] (n=135)	21.3 (14.8-28.6)	4.84 (4.02-5.83)	1.20	0.273	
(0.95, 1.00] (n=438)	25.0 (21.0-29.1)	4.17 (3.75-4.63)	1.05	0.305	

Abbreviations: 5Y-OS, 5-year overall survival; CI, confidence interval; HR, hazard ratio; LNR, lymph node ratio; No., number. <sup>†</sup>Log-rank tests were conducted between two sequential stages and twenty-one  $\chi^2$  values were generated. All stages were compared with LNR = 0 as reference by values of HRs of Cox proportional hazards. <sup>‡</sup>Log-rank tests were conducted between two sequential stages.




**Figure S2** Kaplan-Meier estimates of the AJCC 8<sup>th</sup> pN stage and three LNR stages in the training cohort. (A) AJCC 8<sup>th</sup> pN stage. (B) LNR stage-new. (C) LNR stage-Rosenberg. (D) LNR stage-Berger. AJCC, American Joint Committee on Cancer; LNR, lymph node ratio.

Training cohort	$AIC^{\dagger}$	AUC (95% CI) <sup>‡</sup>	P value <sup>*</sup>
Overall patients (N=62,294)			
AJCC 8 <sup>th</sup> pN stage	563,291	0.584 (0.581-0.588)	reference
LNR stage -Pei <sup>§</sup>	562,703	0.589 (0.585-0.593)	<0.001
LNR stage-Rosenberg <sup>1</sup>	562,771	0.588 (0.584-0.592)	<0.001
LNR stage-Berger <sup>&amp;</sup>	562,863	0.590 (0.586-0.594)	<0.001
Patients with lymph nodes < 12 (n=16,67	4)		
AJCC 8 <sup>th</sup> pN stage	132,884	0.584 (0.577-0.592)	reference
LNR stage-Pei <sup>§</sup>	132,751	0.589 (0.581-0.596)	0.017
LNR stage-Rosenberg <sup>1</sup>	132,765	0.587 (0.579-0.594)	0.018
LNR stage-Berger <sup>&amp;</sup>	132,795	0.589 (0.581-0.596)	0.007
Patients with lymph nodes $\geq$ 12 (n=45,62	0)		
AJCC 8 <sup>th</sup> pN stage	399,397	0.584 (0.580-0.589)	reference
LNR stage-Pei <sup>§</sup>	398,942	0.589 (0.585-0.593)	<0.001
LNR stage-Rosenberg <sup>1</sup>	398,993	0.589 (0.584-0.593)	<0.001
LNR stage-Berger <sup>&amp;</sup>	399,057	0.591 (0.586-0.595)	<0.001

Abbreviations: AIC, Akaike's information criterion; AJCC, American Joint Committee on Cancer; AUC, Areas under the receiver-operating characteristic curve; CI, confidence interval; DFS, disease-free survival; LNR, lymph node ratio. <sup>†</sup>A lower AIC indicates superior modelfitting. <sup>‡</sup>A higher AUC indicates better discrimination. <sup>§</sup>Cutoff values of LNR-Pei: 0.05, 0.30, 0.50, 0.70. <sup>¶</sup>Cutoff values of LNR-Rosenberg: 0, 0.17, 0.41, 0.69. <sup>§</sup>Cutoff values of LNR-Berger: 0.05, 0.19, 0.39. <sup>†</sup>P value of Hanley & McNeil test of AUCs.

## Table S5 Comparisons of LNR stages and the AJCC 8th pN stage in the training cohort



**Figure S3** Decision curve analyses between the AJCC 8<sup>th</sup> TNM and TLNR classifications in the training and validation cohorts. (A) OS in the training cohort. (B) OS in the validation cohort. (C) DFS in the validation cohort. In decision curve analyses, the horizontal solid black line is the net benefit of treating no patients assuming that no patients would die, and the thin grey line is the net benefit of treating all patients similarly regardless of their stages assuming all patients would die. The dotted red line and the dotted black line is the net benefit of treating patients based on the AJCC 8<sup>th</sup> and TLNR classifications. AJCC, American Joint Committee on Cancer; TNM, tumor/node/ metastasis; TLNR, T stage-Lymph Node Ratio classification; LNR, lymph node ratio; OS, overall survival; DFS, disease-free survival.